gene. It is characterized by gastrointestinal polyposis and an increased cancer risk, mainly in the gastrointestinal tract. Mechanisms of PJS-associated carcinogenesis are unclear. We investigated the involvement of candidate genes and molecular pathways in PJS-associated gastrointestinal cancers and dysplastic hamartomas. Cases were selected from the Dutch PJS cohort. Available tissue was immunostained for phospho-S6, β-catenin, P53 and SMAD4. DNA was isolated from carcinoma tissue and dysplastic and non-dysplastic areas of hamartomas specifically. Mutation analyses were done for BRAF, KRAS and P53, and loss of heterozygosity (LOH) analyses for LKB1 and P53. Twenty-four of 144 patients (17%) developed 26 gastrointestinal malignancies at a median age of 49 years (interquartile range: 35-60). Eleven of 792 hamartomas (1.4%) of 9 patients were classified as dysplastic. LOH of LKB1 was detected in three of six (50%) carcinomas and in the dysplastic part of three of five (60%) hamartomas. Aberrant P53 expression was observed in 8 of 15 (53%) carcinomas. Six carcinomas with P53 overexpression harboured a P53 mutation, with loss of the remaining wild-type allele in four. Two hamartomas showing P53 overexpression in high-grade dysplastic foci harboured a P53 mutation with LOH. Loss of nuclear SMAD4 was observed in high-grade dysplastic foci of two of four (50%) hamartomas, in contrast to low-grade dysplastic foci (0/4) and non-dysplastic epithelium. Our findings suggest a role for mutant P53 in PJS-associated gastrointestinal carcinogenesis. Inactivation of transforming growth factor-β/ bone morphogenetic protein signalling and complete loss of LKB1 might be involved in dysplastic transformation of gastrointestinal hamartomas specifically.
Introduction
Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant inherited disorder. Incidence is estimated between 1 in 50 000 and 1 in 200 000 live births (1) . The syndrome is caused by an inactivating germ line mutation in the LKB1 tumour suppressor gene (also known as STK11), located on chromosome 19p13.3 of the human genome (2, 3) . A pathogenic germ line mutation in LKB1 is detected in 80-94% of families affected with PJS (4, 5) .
The typical PJS phenotype consists of mucocutaneous pigmentations and gastrointestinal (GI) polyposis. These polyps, histologically defined as hamartomas, can develop already in the first decade of life and may cause anaemia, bleeding, abdominal pain and intestinal obstruction (6) . Furthermore, PJS patients are at increased risk for developing cancer at a young age (7, 8) . Although a wide spectrum of malignancies has been described, patients are mostly affected by cancers in the GI tract, including colorectal, pancreatic and gastric cancer. A cumulative risk of up to 57% at the age of 70 years has been described for GI cancers (8) .
At present, the pathogenesis and molecular mechanisms underlying PJS-associated GI cancer development are unclear. Though adenomatous and carcinomatous changes are rarely observed in PJS hamartomas (9-11), a hamartoma-carcinoma sequence is debated. In addition to the initial germ line mutation, several mechanisms for inactivation of the remaining wild-type LKB1 allele, such as loss of heterozygosity (LOH) and promoter hypermethylation, have been described of which LOH is observed most frequently. Interestingly, however, although LOH is detected more frequently in carcinomas than in hamartomas, it is not detected in 100% of these carcinomas (12) (13) (14) , suggesting that complete loss of functional LKB1 might not be required for the development of carcinomas in PJS. Coincidence of the proper secondary oncogenic hits in other genes in addition to this haploinsufficiency of LKB1 might be sufficient for carcinoma development in this syndrome (15, 16) .
The aim of this study was to get insight into the molecular pathways underlying PJS-associated GI carcinogenesis. To this aim, we collected a unique panel of 15 GI carcinomas from a large cohort of Dutch PJS patients. The expression, activity and mutation status of genes and signalling pathways associated with sporadic GI carcinogenesis as well as with GI cancer related to other inherited disorders were studied by immunohistochemistry (IHC) and DNA mutation analysis. To investigate whether there is an overlap between the molecular alterations in these carcinomas and in PJS hamartomas, specifically in dysplastic lesions of these hamartomas, we also analysed the affected genes and pathways in a unique set of nine dysplastic hamartomas from our patient cohort.
Materials and methods

Case selection and data collection
Cases were selected from the Dutch PJS cohort, initiated by two Dutch academic hospitals. PJS patients throughout the Netherlands with a definite diagnosis of PJS-defined by diagnostic criteria recommended by the WHO, a proven LKB1 mutation or both-were included in this cohort. Informed consent was obtained of all patients or of their next of kin if patients had passed away, and the study was approved by the Institutional Review Board of both participating hospitals. In total, 144 PJS patients from 61 families were included in this cohort. Baseline characteristics of the cohort are shown in Supplementary Table S1, available at Carcinogenesis Online. Patients with a diagnosis of a primary malignancy of the GI tract [i.e. oesophagus, stomach, small intestine (including duodenum), colorectum, pancreas, liver and biliary tract] were selected. Data were collected on the following variables: date of birth, date of death, gender, LKB1 germ line mutation, date of diagnosis, tumour type and origin, tumour invasion, data on confirmation (medical record or histology) and treatment.
To select hamartomas with dysplastic changes, all available electronic pathology reports of hamartomas removed during endoscopy, intraoperative enteroscopy or surgery were screened. Two expert pathologists independently reviewed all haematoxylin and eosin-stained slides of hamartomas with some degree of dysplasia according to the original pathology report. In case of disagreement, consensus was reached by consultation. Only cases with both hamartomatous characteristics and dysplastic changes were included in this (26, 27) 6. Tables I and III and Supplementary Table S2 , available at Carcinogenesis Online). 
study. Dysplasia was classified as low-grade dysplasia (LGD) or high-grade dysplasia (HGD).
Immunohistochemistry Formalin-fixed paraffin-embedded (FFPE) tissue of both carcinoma and dysplastic hamartoma cases was collected from pathology archives for further analysis. Sections (4-5 µm) were cut and deparaffinized. Antigen retrieval was performed by boiling in 10 mM Tris/1 mM ethylenediaminetetraacetic acid buffer pH 9 (for β-catenin and SMAD4) or 10 mM citric buffer pH 6 (for alpha smooth muscle actin and pS6) for 10 min. Non-specific binding sites were blocked in 3% H 2 O 2 for 10 min and 5% non-fat dry milk for 30 min and in phosphatebuffered saline with 10% normal goat serum for SMAD4. Primary antibodies used for IHC analysis included monoclonal mouse anti-human alpha smooth muscle actin (1:1000, DAKO clone 1A4), monoclonal mouse anti-β-catenin (1:1500, BD Biosciences 610154), monoclonal rabbit anti-phospho-S6 ribosomal protein (1:250, Cell Signalling Technology #5364), p53 (1:400, DAKO clone DO-7), Mib-1 (1:100, DAKO clone MIB-1) and SMAD4 (1:400, Santa Cruz Biotechnology). Incubations with primary antibodies were carried out overnight at 4°C for 1 h at room temperature for SMAD4. Sections were washed three times with phosphate-buffered saline containing 0.05% Tween-20 and incubated with horseradish peroxidase-labelled goat anti-rabbit immunoglobulin G or goat anti-mouse immunoglobulin G (EnVision™+, DAKO) for 30 min. Sections were washed three times with phosphate-buffered saline containing 0.05% Tween-20. After diaminobenzidene precipitation, a haematoxylin counterstaining was performed.
Slides were scored by two authors independently and final consensus was reached by consultation.
Alpha smooth muscle actin was stained for confirmation of hamartomas. Proliferation rates were determined by the average percentage of Mib-1 positive cells in three microscopic fields (×20). Nuclear β-catenin and SMAD4 staining was considered positive when one or more positive nuclei were observed in a microscopic field (×20). P53 staining was scored on a scale ranging from − to +++ (−, negative; +, positive/normal; ++, moderate overexpression; +++, strong overexpression). Epithelial pS6 staining was scored on a scale ranging from − to ++ (−, negative; +, positive; ++, overexpression).
DNA isolation
Tissue of GI carcinomas was carefully dissociated from surrounding normal tissue, resulting in samples containing >50% tumour cells. DNA of dysplastic hamartoma tissue was isolated from epithelial cells in the non-dysplastic area and epithelial cells in the dysplastic lesion specifically, using PALM laser microdissection. For DNA isolation, samples were incubated overnight at 56°C in lysis buffer (Cell Lysis Solution, Promega, cat # A7933) containing 5% chelex [Chelex 100 resin (Bio-Rad) catalog # 143-2832] and 10% proteinase K. Samples were heated to 95°C for 10 min to inactivate the proteinase K and to denature the DNA. DNA mutation analysis DNA was amplified for mutational analysis. DNA of all tumours was sequenced and checked for mutations in KRAS codons 12 and 13 and BRAF codon 600. Mutation analysis of exon 3 of β-catenin was performed if nuclear expression of β-catenin was observed with IHC. P53 mutation analysis for exons 5-8 was performed for all GI carcinomas. For the dysplastic hamartomas, P53 mutation analysis was only performed if aberrant P53 expression (i.e. strong overexpression or absence) was observed with IHC. In cases of a known germ line LKB1 mutation or the detection of a P53 mutation, loss of the wild-type LKB1 and P53 alleles, indicative for LOH, was determined from the nucleotide sequence analyses. PCRs were performed at an annealing temperature of 58°C, for 34 cycles using GoTaq® DNA Polymerase with 5× buffer (Promega, Madison, WI). For most tumours, a nested PCR was performed with 2 μl PCR product. DNA purification and sequencing reactions were performed by LGC Genomics (Berlin, Germany). Primers and nested primers used for amplification and sequences of the different genes are available upon request.
Results
Clinical characteristics-GI carcinomas
Twenty-four of the 144 patients (17%, 67% male) from 18 families developed 26 GI malignancies (Table I) . Two patients were diagnosed with two primary tumours. Median age at diagnosis of the first tumour was 49 years [interquartile range (IQR): 35-60]. Two carcinomas were detected during surveillance endoscopies; in all the other cases, patients presented with symptoms. Median survival after GI cancer diagnosis was 8 months (IQR: 3-49 months). Twenty-one of these patients (88%) deceased at a median age of 55 years (IQR: 38-61); 20 of whom died as a direct cause of GI cancer. Three patients are still alive at a median time of 4 years (IQR: 3-15) after cancer diagnosis. These data suggest that PJS patients can develop aggressive GI cancers at a relatively young age.
Clinical characteristics-dysplastic hamartomas
A total of 792 hamartomas of 52 patients were histologically examined. Nineteen (2.4%) hamartomas of 15 patients were originally classified as dysplastic. Upon revision by two expert pathologists, 11 (1.4%) hamartomas of 9 patients (8 male) were classified as dysplastic and included in this study (Supplementary Table S2, available at Carcinogenesis Online), with a 100% consensus between the two pathologists. In the eight other cases, the morphologic abnormalities were reclassified as reactive proliferation instead of dysplastic changes. This implies that GI hamartomas of PJS patients are not precursor lesions although malignant transformation does occur in sporadic cases.
Seven (64%) hamartomas contained foci of LGD and four showed foci of HGD changes (Supplementary Table S2 , available at Carcinogenesis Online). Median size of the dysplastic hamartomas Tables I and II and Supplementary Table S2 , available at Carcinogenesis
f Mutation analysis of β-catenin (exon 3) was only performed if nuclear expression of β-catenin was observed with IHC. was 30 mm (IQR: 15-40). Dysplastic hamartomas were detected throughout the GI tract and five (45%) hamartomas were found during surveillance endoscopies.
Molecular alterations in GI carcinomas
To investigate whether molecular alterations in genes known to be involved in sporadic and hereditary GI cancer can also be identified in PJS-associated cancers, FFPE tissue of 15 available GI carcinomas was selected (Table II) . Proliferation of tumour cells differed widely between the tissue samples. Loss of the wild-type allele of LKB1, indicative for LOH, was detected in three of six (50%) informative GI carcinomas ( Figure 1A) , which is in line with previously reported frequencies. Inactivation of LKB1 impairs the inhibition of mammalian target of rapamycin (mTOR), resulting in phosphorylation of the ribosomal protein S6. All 15 carcinomas showed epithelial phospho-S6 expression, although in a heterogeneous manner. Phospho-S6 expression did not correlate with loss of wild-type LKB1. This suggests that complete loss of LKB1 occurs in PJS-associated GI carcinomas, but is not required. Also, complete loss of LKB1 does not correlate with hyperactivation of mTOR in these tumours. In 8 of 15 (53%) GI carcinomas, aberrant P53 expression was observed. Six samples showed strong overexpression of P53 and two others showed total absence of P53 expression, suggesting that in these carcinomas, P53 was genetically altered ( Figure 1B ). In 6 of 15 (40%) carcinomas, a mutation in P53 could be detected, which was accompanied by loss of the remaining wild-type allele in four of six (67%) cases ( Figure 1C ). These data suggest that genetically altered P53 is involved in GI carcinogenesis in PJS.
In none of the GI carcinoma samples, a mutation in the BRAF gene was observed, and only one somatic KRAS mutation was found in a colon carcinoma. Nuclear β-catenin, indicative for active Wnt signalling, was detected in some tumour cells scattered throughout glandular structures of two colorectal carcinomas and one pancreatic carcinoma. A mutation in exon 3 of β-catenin was found in one colorectal carcinoma. Loss of nuclear SMAD4, indicative for the inactivation of transforming growth factor-β/bone morphogenetic protein (TGF-β/BMP) signalling, was observed in two pancreatic carcinomas. This might implicate that BRAF, KRAS Wnt signalling and the TGF-β/BMP pathway, involved in sporadic and other hereditary GI cancers, are not frequently altered in PJS-associated cancer of the digestive tract.
Molecular alterations in dysplastic hamartomas
To compare molecular alterations of PJS-associated carcinomas and dysplastic hamartomas of the GI tract, we also collected FFPE tissue of nine dysplastic hamartomas (Table III) . In all hamartomas, the characteristic branching structure of smooth muscle cells could be observed by haematoxylin and eosin and αSMA stainings (Figure 2A and B). As expected, Mib-1 staining showed increased proliferation rates in all dysplastic foci compared with the non-dysplastic epithelial compartments of the same hamartomas ( Figure 2C) .
Loss of the wild-type allele could not be detected in the non-dysplastic areas of any of the hamartomas available for analysis. In contrast, loss of the wild-type LKB1 allele was detected in the dysplastic segments (two with LGD and one with HGD) of three of five (60%) of these hamartomas ( Figure 3A) . Phospho-S6 expression was more abundant in the dysplastic epithelium of four hamartomas (three with HGD) (data not shown), and in two cases, this correlated with loss of the wild-type allele of LKB1 (Table III) . Stromal cells were also positive for phospho-S6 staining, but there was no difference in stromal expression between the non-dysplastic and the dysplastic parts. These results suggest that complete loss of LKB1 and activation of mTOR are involved in dysplastic degeneration of GI hamartomas in PJS. However, loss of LKB1 did not correlate with mTOR hyperactivation.
Since we observed that P53 was frequently genetically altered in PJS-associated GI carcinomas, we investigated P53 expression in the dysplastic GI hamartomas. Aberrant expression of P53 was specifically observed in the HGD parts of three of four (75%) hamartomas, of which two showed strong overexpression and one showed complete loss of P53 expression ( Figure 3B ). Aberrant expression of P53 could not be observed in the LGD or non-dysplastic parts of the hamartomas (Figure 2 ). In the two HGD hamartomas showing strong overexpression of P53, a P53 mutation with loss of the wild-type allele was specifically detected in DNA isolated from the dysplastic cells ( Figure 3C ). This might indicate that genetically altered P53 is involved in HGD transformation of PJS hamartomas. In contrast, no BRAF or KRAS mutations could be detected, suggesting that these oncogenes do not play a role in dysplastic transformation of hamartomas. In the LGD epithelium of three of five (60%) hamartomas with LGD, focal nuclear expression of β-catenin was detected, in contrast to the four hamartomas with HGD, where no nuclear expression of β-catenin was found ( Figure 3B) . However, the expression pattern was not abundant and no mutation in exon 3 of β-catenin was detected in DNA of these hamartomas. Notably, two of four (50%) HGD hamartomas showed absence of nuclear SMAD4 in the dysplastic foci, in contrast to the non-dysplastic epithelium of these hamartomas ( Figure 3B ). This was not observed in any of the LGD hamartomas. Therefore, loss of TGF-β/BMP signalling might be involved in HGD transformation of GI hamartomas in PJS.
Discussion
Patients with PJS are prone to develop cancer at a young age, especially in the GI tract. In a large cohort of Dutch PJS patients, 17% of patients developed a primary malignancy in the GI tract at a median age of 49 years. Although tumours developed throughout the digestive tract, they were mainly found in the colorectum and pancreas. Survival after GI cancer diagnosis was strikingly short in our cohort, suggesting a more aggressive tumour phenotype in PJS. However, the pathogenesis of PJS-associated cancers remains unknown.
Inactivating germ line mutations in the LKB1 tumour suppressor gene, causing PJS, were detected in the majority of patients or their affected family members of our cohort. Loss of the remaining wild-type allele of LKB1 was found in only three out of six GI carcinomas, which is in line with previously reported frequencies (12) (13) (14) . In contrast, in three out of five hamartomas, loss of the wild-type LKB1 allele was detected in the dysplastic epithelium but not in the non-dysplastic epithelium of the same hamartomas. Therefore, complete loss of LKB1 might not be a prerequisite for GI carcinogenesis in PJS, but is involved in dysplastic transformation of hamartomas. However, we cannot exclude loss of LKB1 protein expression since suitable antibodies for IHC are not available. Furthermore, somatic inactivation by epigenetic silencing due to promoter methylation has been described for the LKB1 gene. LKB1 deficiency impairs the inhibition of mTOR, and it has been suggested that specific mTOR inhibitors (e.g. rapamycin) might be an effective therapy for the treatment of both hamartomas and carcinomas in PJS patients (17, 18) . However, activation of mTOR-by means of higher phospho-S6 protein levels-did not correlate with genetic loss of LKB1 in the majority of carcinomas and dysplastic hamartomas, indicating that alternative pathways (e.g. PI3K/AKT signalling) might be involved in mTOR activation in PJS tumours as well.
We detected mutations in the P53 tumour suppressor gene-in most cases with loss of the wild-type P53 allele and concomitant P53 overexpression-in both GI cancers and hamartomas with HGD lesions. Because some of the P53 mutations were identified exclusively in the dysplastic parts of the hamartomas, and since our patients, although intensively monitored, do not show any signs of suffering from Li-Fraumeni syndrome, we strongly believe that these mutations are somatic rather than germ line. These data suggest that mutant P53 is involved in GI carcinogenesis and late stages of dysplastic transformation of hamartomas in PJS. In LKB1 mutant mice, additional loss of p53 increased and accelerated GI hamartoma growth without changing the histological grade of these hamartomas (19, 20) . Notably, additional loss of p53 could not induce intestinal carcinoma development in LKB1-deficient mice. Inactivation of LKB1 might collaborate with mutant P53 rather than with loss of P53 for PJS-associated carcinogenesis.
In sporadic colorectal cancer (CRC) cases, both activation of the Wnt/β-catenin pathway and the oncogene KRAS are essential early events in development (21) . At a later stage in the adenoma-carcinoma sequence of sporadic CRC, mutations in the P53 tumour suppressor gene play an important role. In the present study, two of four (50%) of colorectal carcinomas showed nuclear β-catenin, indicative for activation of the oncogenic Wnt/β-catenin signalling pathway. However, nuclear β-catenin was not as abundant as observed in sporadic CRC or in premalignant adenomas. Previously, β-catenin mutations rather than mutations in APC have been detected in PJS tumours (12, 22) . We observed no mutations in the β-catenin gene in the carcinomas and dysplastic hamartomas showing nuclear β-catenin. In one of four CRCs, a KRAS mutation was detected, which coincided with nuclear β-catenin. In another CRC specimen, nuclear β-catenin coincided with a P53 mutation. These results suggest a synergism between active Wnt/β-catenin signalling, KRAS and P53 in PJS-associated CRC formation, like in sporadic CRC. However, no KRAS mutations were observed in the other GI carcinomas and nuclear β-catenin was observed in only one pancreatic cancer, whereas P53 mutations were abundant in the other carcinomas. Thus, although similar molecular mechanisms may be involved in PJS-associated CRC as well as in sporadic cases of CRC, our results indicate a strong link between LKB1 and P53 in other GI cancers, which may be specific for PJS-associated cancer.
Strikingly, in none of the investigated pancreatic carcinomas, a KRAS mutation was detected, whereas mutations in this gene are found in more than 90% of sporadic pancreatic carcinomas (23) . This suggests that oncogenic activation of KRAS in addition to inactive LKB1 is not required for pancreatic carcinogenesis in PJS. This is also shown in mice, where specific loss of LKB1 in pancreatic epithelium is sufficient for pancreatic carcinoma formation (24) . In sporadic pancreatic cancers, the SMAD4 gene is inactivated in ~60% (25) . Here, we observed loss of nuclear SMAD4 in two out of five pancreatic cancers. Notably, nuclear SMAD4 was absent in the nuclei of dysplastic cells of two out of four HGD intestinal hamartomas, whereas it was present in all intestinal carcinomas. This might indicate involvement of inactive TGF-β/BMP signalling in dysplastic transformation of PJS hamartomas, but not in intestinal carcinoma development, and suggest that these are two different entities of the PJS.
Although dysplastic and carcinomatous changes do occur in hamartomas, it is rare. In the present study, only about 1% of hamartomas showed some degree of dysplasia. Because not all hamartomas found in our patients were revised, this could be an underestimation. However, also in previous studies, malignant transformation was found in a minority of PJS hamartomas (<1-9%) (10, 11) . Furthermore, signs of hamartomatous tissue that could indicate a hamartomatous origin were not observed in the PJS-associated carcinomas. Although the incidence of GI carcinomas is high in PJS patients, a much higher incidence would be expected if hamartomas were indeed precursor lesions, given the high polyp load in most PJS patients. In addition, the location of the GI malignancies in PJS patients does not always correlate with the location of the hamartomatous polyps (9) . Also in the present study, most GI cancers were found in the colorectum and pancreas, whereas dysplastic hamartomas were mainly found in the small bowel, in line with the preferred location of PJS hamartomas. Finally, although some molecular alterations were identified in both PJS-associated GI carcinomas and dysplastic lesions of hamartomas, we mainly detected substantial differences. Based on these observations, we believe that an absolute hamartoma-carcinoma sequence in PJS patients is unlikely.
In conclusion, our findings suggest a role for mutant P53 in PJSassociated GI carcinogenesis, in addition to a haploinsufficient function of the LKB1 tumour suppressor gene. Loss of nuclear SMAD4 and complete loss of LKB1 may be involved in dysplastic transformation of GI hamartomas specifically.
Our conclusions are based on a small number of heterogeneous tumour samples, which is explained by the rarity of the PJS. Though, to our knowledge, we describe the largest sample set of PJSassociated carcinomas of the GI tract specifically. In addition, the set of GI hamartomas with different grades of dysplasia used in this study is of amount not incorporated in such a study elsewhere. With these unique sample sets, we were able to identify molecular alterations associated with GI tumour development in PJS. Whether these alterations contribute to the development of these PJS tumours is suggestive, but needs to be investigated further in functional studies. 
